Topical corticosteroid therapy: clobetasol propionate 0.025%
DOI:
https://doi.org/10.18203/2320-6012.ijrms20223654Keywords:
Clobetasol propionate 0.025%, Psoriasis, Plaque psoriasis, Topical corticosteroidsAbstract
Topical corticosteroids have been the cornerstone of treatment over the last six decades for various dermatoses characterized by dry, scaly, crusted, or erythematous skin as well as those associated with inflammation and pruritus. The potency of a topical steroid depends on the specific molecule, the amount of drug reaching the target, absorption through the skin (0.25%–3%), and the formulation. Clobetasol propionate (CP) 0.025% cream formulation is a potent, fifth-generation topical corticosteroid. It is approved by the United States Food and Drug Administration to be applied twice daily for the treatment of moderate-to–severe psoriasis in adults. This case series covers the clinical experience of various dermatologists, including their expert opinion on the safety and efficacy of ImpoyzTM (CP) cream 0.025% in different skin disorders.
Metrics
References
Abidi A, Ahmad F, Singh SK. A comparative clinical evaluation of once daily versus alternate day application of topical clobetasol propionate cream in psoriasis. J Clin Diagn Res. 2013;7(1):100-5.
Feldman SR. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005;66(3):154-71.
Del Rosso JQ. Topical corticosteroid therapy for psoriasis-A review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.
Desai S, Draelos Z, Feldman S, Jackson JM. A phase 3, randomized, double-blind, vehicle-controlled, multicenter, parallel group trial investigating the efficacy and safety of clobetasol propionate cream, 0.025% in the treatment of moderate to severe plaque psoriasis for 14 days. SKIN J Cutaneous Med. 2021;5(6):s33.